VIDEO: Sequence of treatments for patients with breast cancer ‘continues to evolve’

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

So I think the sequence of treatments for patients with breast cancer has evolved and continues to evolve on a very regular basis. So how we approach breast cancer currently is really, we've always thought of trying to divide treatment strategies by subtypes. So if someone has a hormone receptor positive breast cancer, we have one treatment algorithm. If it's HER2-positive, a different algorithm. And now if they're triple negative, another algorithm. And thinking about the order of treatments, if someone has metastatic disease, doesn't just rely on the subtype. But also, again, has become much more complex because you need to understand genomics, germline genetic information, as well as mutational status of that tumor. And so all those factors really get considered when trying to think about the optimal treatment approach for a particular patient. So for example, if someone has metastatic triple negative disease, I would need to know does that tumor express PD-L1? I would also want to know, does that patient have a germline alteration in BRCA or PALB2? Is the tumor HER2-low? Does it have a high TMB? So all of these things are factors that we think about when trying to make the right treatment decision for that patient. And again, I think that's just a movement towards really getting better treatments for patients because we can try to individualize the therapy more.